{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Arm A: Rd",
        "type": {
          "code": "Active Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Active Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Lenalidomide and Dexamethasone (Rd) alone. Lenalidomide 25 mg PO Days 1-21 of each 28-day cycle; Dexamethasone 40 mg weekly."
      },
      {
        "id": "arm_2",
        "name": "Arm B: DRd",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Daratumumab, Lenalidomide, and Dexamethasone (DRd). Daratumumab 16 mg/kg IV (or 1800 mg SC) added to the Rd regimen."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_7"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_8"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Transplant-ineligible",
        "instanceType": "StudyCohort",
        "characteristic": "Subjects with previously untreated multiple myeloma who are ineligible for high dose therapy"
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Arm A: Rd - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A: Rd during Screening"
      },
      {
        "id": "elem_2",
        "name": "Arm A: Rd - Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A: Rd during Treatment Phase"
      },
      {
        "id": "elem_3",
        "name": "Arm A: Rd - Follow-up Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A: Rd during Follow-up Phase"
      },
      {
        "id": "elem_4",
        "name": "Arm A: Rd - Long-term Survival Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A: Rd during Long-term Survival Follow-up"
      },
      {
        "id": "elem_5",
        "name": "Arm B: DRd - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B: DRd during Screening"
      },
      {
        "id": "elem_6",
        "name": "Arm B: DRd - Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B: DRd during Treatment Phase"
      },
      {
        "id": "elem_7",
        "name": "Arm B: DRd - Follow-up Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B: DRd during Follow-up Phase"
      },
      {
        "id": "elem_8",
        "name": "Arm B: DRd - Long-term Survival Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B: DRd during Long-term Survival Follow-up"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 8,
      "cohortCount": 1,
      "elementCount": 8
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "controlType": {
        "code": "Active Control",
        "codeSystem": "USDM",
        "decode": "Active Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "cohortIds": [
        "cohort_1"
      ],
      "therapeuticAreas": [
        "Oncology",
        "Hematology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": null,
        "stratificationFactors": []
      },
      "controlType": "Active Control",
      "therapeuticAreas": [
        "Oncology",
        "Hematology"
      ]
    },
    "arms": [
      {
        "name": "Arm A: Rd",
        "type": "Active Comparator",
        "description": "Lenalidomide and Dexamethasone (Rd) alone. Lenalidomide 25 mg PO Days 1-21 of each 28-day cycle; Dexamethasone 40 mg weekly.",
        "isTitration": false,
        "doseEpochs": null
      },
      {
        "name": "Arm B: DRd",
        "type": "Experimental Arm",
        "description": "Daratumumab, Lenalidomide, and Dexamethasone (DRd). Daratumumab 16 mg/kg IV (or 1800 mg SC) added to the Rd regimen.",
        "isTitration": false,
        "doseEpochs": null
      }
    ],
    "cohorts": [
      {
        "name": "Transplant-ineligible",
        "characteristic": "Subjects with previously untreated multiple myeloma who are ineligible for high dose therapy"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Up to 21 days prior to randomization"
      },
      {
        "name": "Treatment Phase",
        "description": "Cycles of 28 days until disease progression or unacceptable toxicity"
      },
      {
        "name": "Follow-up Phase",
        "description": "Begins after treatment discontinuation; includes disease evaluations until PD and survival follow-up"
      },
      {
        "name": "Long-term Survival Follow-up",
        "description": "Transition after final CSR analysis; monitoring for overall survival"
      }
    ]
  }
}